Panacea Biotec, a biotechnology company based in India, has secured a ₹20.79 crore ($2.5 million USD) letter of award from the Central Medical Services Society, under the Ministry of Health and Family Welfare. The contract entails supplying Diphtheria and Tetanus vaccines for adults and adolescents (Td Vaccine) in multiple tranches, with deliveries scheduled to begin in September 2026 and continue until December 2028. The company clarified that the order is from a domestic entity and does not involve related-party transactions. In its recent financial report, Panacea Biotec disclosed a consolidated net loss of ₹7.36 crore in Q3 FY26, compared to a net profit of ₹9.65 crore in Q3 FY25, with revenue from operations declining by 8.4% year-on-year to ₹99.31 crore. Following the announcement of the contract, shares of Panacea Biotec increased by 1.23%, closing at ₹326 on April 10, 2026.